Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase 2/3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 5Mesothelioma 4Neoplasms 2NSCLC 2Recurrence 1Nonsquamous Non-small Cell Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Mesothelioma, Malignant 1Adenocarcinoma of Lung 1

Interventions

Temozolomide 3Gemcitabine 3Etoposide 3pembrolizumab 2Rituximab 2Lomustine 2Haloperidol 2Dexamethasone 2Cyclosporine 2vocimagene amiretrorepvec 1trofosfamide 1tinostamustine 1selinexor 1ruxolitinib 1regorafenib 1peginterferon alfa-2b 1osimertinib 1menatetrenone 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1glumetinib 1fludarabine 1etoposide phosphate 1eculizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carbon-11 acetate 1blinatumomab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recurrence × Pemetrexed × Clear all
NCT01774578 2020-05-28

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Lumos Pharma

Phase 2/3 Terminated
135 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡